Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Cannabotech's IntegrativePain products show an 80%-100% reduction in inflammatory pain


News provided by

Cannabotech

28 Feb, 2022, 07:30 GMT

Share this article

Share toX

Share this article

Share toX

- The mouse model study was conducted by Cannabotech's scientific team, led by Dr. Isaac Angel, pharmacologist specializing in drug development

- The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC

- The treatment is expected to be launched in Israel, US and UK in H2 2022

HERZLIYA, Israel, Feb. 28, 2022 /PRNewswire/ -- Cannabotech, a biomedical company that develops medical products based on cannabis and fungal extracts, has reported study results which show that using mushroom compounds in conjunction with cannabinoids achieves an 80%-100% reduction in pain sensation.

Furthermore, adding defined concentrations of other cannabinoids allowed using lower concentrations of THC to achieve very high medical efficacy.

The treatment is expected to be launched in Israel, US and UK in the second half of 2022 and be incorporated as part of Cannabotech's Integrative Oncology solutions concept, with existing therapeutic protocols. This would coincide with conventional chemotherapy while providing supportive scientific information to physicians.

Currently, around 50%-80% of cancer patients receive additional integrative treatment alongside chemotherapy (mainly herbal products, including cannabis). The key reasons for using integrative products include strengthening the immune system, improving treatment efficacy and reducing adverse events.[1],[2]

The mouse model study of inflammatory pain examined the efficacy of IntegrativePain products designed to reduce pain, including those emanating from an inflammatory source like arthritis, back pain or chemotherapy side-effects.

The results clearly showed that adding cannabinoids to THC and CBD significantly increases medical efficacy. The products' uniqueness lies in its capacity to achieve high efficacy with low THC / high CBD concentrations combined with defined concentrations of other cannabinoids like THCV and CBG constructed to reach maximum medical efficiency, without the undesired "high." Moreover, the results showed a significant decrease in pain intensity independent of a direct decreased inflammatory magnitude, suggesting that the products immediately affect pain mechanisms on top of their anti-inflammatory activity.

Furthermore, the fungal composition, made up of seven extracts from different mushrooms, achieved very high efficacy by itself, as did the cannabinoids, with impressive pain-relieving results on their own. As the Company expected, the fungal and cannabinoid combined achieved a stronger effect than each individually. This result reinforces Cannabotech's claim that treating the endocannabinoid system (using cannabinoids) jointly with other systems, like the immune system (using mushrooms), achieves an increased and more potent medical effect than each of these components individually.

The experiment also emphasized the importance of tailoring treatment, with Cannabotech developing three pain-treatment formulas: one for pain from an inflammatory source; another for pain from a neuropathic origin; and a third for pain from integrated sources. Indeed, this experiment demonstrated different products' efficacy on the inflammation and pain emanating from inflammatory sources, as well as variations in efficacy between products when it came to reducing pain from an inflammatory source, as tested in the study. Cannabotech is currently developing a personalization system to provide physicians with the information to help them make informed and customized decisions using IntegrativePain products.

IntegrativePain products are part of Cannabotech's Integrative Oncology product series designed to treat cancer patients and chemotherapy's side-effects. The trial is part of a series of studies conducted by Cannabotech on all Integrative Oncology products, which are expected to end within a few months.

Cannabotech CEO Elhanan Shaked said: "This is a significant milestone in Cannabotech's growth to becoming a leader in integrative oncology medicine. The integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment in several cancers, and form part of the Company's goal to define a new standard for the medical cannabis industry.

"Pain is the leading indication amongst medical cannabis users. However, while most products on the market are inflorescences-based cannabis with high THC concentrations, Cannabotech presents a different, oil-based concept rich in other active ingredients, whose unique composition shows outstanding results without the unwanted side effects."

Dr. Isaac Angel, Cannabotech's pharmacological consultant, said: "Pain is one of the central problems the healthcare industry has been attempting to solve for decades. Most pain patients' aches emanate from a combined, partly inflammatory source, which significantly impairs their quality of life. Cannabotech's products have shown heightened efficiency in the current mouse model. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products. We will continue to work to provide a cure for patients."

About Cannabotech:

Cannabotech is an Israeli biomedical company that develops botanical solutions for preventive medicine and integrative oncology medicine. These solutions are based on combinations of active agents from the cannabis plant and mushrooms that work on two central systems in the human body: the endocannabinoid system and the immune system.

As part of the concept of integrative medicine, in the last two years, Cannabotech has been developing a series of 8 preparations designed to help patients with cancer and chronic pain based on unique combinations of botanicals from medical cannabis and fungus-based products. Upon completion of their development, the company's goal is to designate the products to be integrated into oncology patients' existing treatment protocol.

At the same time, Cannabotech is working to develop a defined treatment protocol made available to physicians and technology for treatment customization.

1. https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/1472-6882-2-8 
2. https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.33906

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.